샘플 요청 목록

 카트 문의
시장보고서
상품코드
1618252

세계의 약물 용출 스텐트 시장 : 인사이트·경쟁 환경·시장 예측(-2030년)

Drug-Eluting Stents - Market Insights, Competitive Landscape, and Market Forecast - 2030
발행일: | 리서치사: DelveInsight | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

약물 용출 스텐트 시장 규모는 2023년 24억 달러에서 예측기간 중에는 CAGR 7.88%로 성장을 지속하여 2030년에는 37억 8,000만 달러 규모에 달할 것으로 예측됩니다. 약물 용출 스텐트 시장은 심방 세동과 관상 동맥 질환(CAD), 말초 동맥 질환(PAD)을 포함한 심혈관질환의 환자수 증가, 혁신적인 제품개발 활동, 저침습기술 채용 증가 등을 주인으로 하여 대폭적인 시장성장을 이루고 있으며, 2024년부터 2030년까지의 예측기간 동안에도 이들 요인이 시장 전체의 성장을 가속할 것으로 예상됩니다.

약물 용출 스텐트: 시장 역학

World Heart Report(2023)가 제공한 데이터에 따르면, 2021년에는 세계에서 5억 명 이상이 심혈관 질환을 가지고 생활하고 있다고 보고되었습니다. 최근 데이터에 따르면 2030년까지 세계에서 1,200만명 이상이 심방세동에 걸린 것으로 추정되고 있습니다.

British Heart Foundation의 Global Heart & Circulatory Diseases Factsheet(2024)에 따르면 세계 약 2억 명의 사람들이 관상 동맥 질환(CAD)을 앓고 있습니다.

또한, American Heart Association(2023년)의 데이터에 따르면, 세계 평균 약 2억명이 말초동맥질환(PAD)을 갖고 생활하고 있습니다. 40세에서 70세까지의 PAD 유병자 수는 세계에서 5,640만명으로 추계되고 있습니다.

이러한 심혈관 질환의 환자 수가 증가하면 약물 용출 스텐트 수요가 크게 증가하고 있습니다. 요구가 커지고 있습니다. 스텐트 기술의 진보에 더해 심장과 순환기계 질환의 부담이 증가하고 있기 때문에 스텐트는 이러한 질환의 치료에 필수적인 요소가 되어 있어, 예방과 치료의 양쪽 모두의 헬스케어 전략에 있어서 역할을 높이고 있습니다.

코팅별로는 폴리머 기반 코팅 부문이 2023년에 큰 수익 점유율을 차지할 것으로 예상됩니다.

약물 용출 스텐트에 적용된 고분자 기반 코팅은 치료제의 제어 방출을 촉진하고 관상 동맥의 재 협착 방지에 매우 효과적입니다. 직접, 단계적으로 그리고 표적으로 방출할 수 있도록 설계되었습니다. 이것은 재협착의 일반적인 원인인 평활근 세포의 증식과 신생 내막 과형성을 억제하는 데 도움이 될 수 있으며 약물의 방출 속도를 조절하여 치료 효과를 최적화할 수 있습니다.

지역별로는 북미가 약물 용출 스텐트 시장에서 큰 수익 점유율을 차지하는 것으로 추정되고 있습니다. 진전, 주요 기업의 존재, 확립된 진보된 의료 인프라의 가용성 등 여러 요인 때문입니다.

본 보고서에서는 세계의 약물용출 스텐트 시장을 조사했으며, 시장 개요, 시장영향인자 및 시장기회 분석, 법규제 환경, 시장 규모 추이와 예측, 각종 구분·지역/주요 국가별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등을 정리했습니다.

목차

제1장 약물 용출 스텐트 시장 보고서 : 인트로덕션

  • 조사 범위
  • 시장 분류
  • 시장의 상정

제2장 약물 용출 스텐트 시장 : 주요 요약

  • 시장 개요

제3장 경쟁 구도

제4장 규제 분석

  • 미국
  • 유럽
  • 일본
  • 중국

제5장 약물 용출 스텐트 시장 : 주요 요인 분석

  • 시장 성장 촉진요인
    • 만성질환의 발생률 증가
    • 제품 개발 활동의 활성화
    • 생활습관병 증가
    • 저침습 수술에 대한 관심
  • 시장 성장 억제요인과 과제
    • 약물 용출 스텐트와 관련된 위험과 합병증
    • 엄격한 규제 승인 프로세스
  • 시장 기회
    • 생체 흡수성 혈관 스캐폴드의 개발
    • 스텐트 유치를 위한 AI와 로봇의 통합

제6장 약물 용출 스텐트 시장 : Porter's Five Forces 분석

제7장 약물 용출 스텐트 시장 평가

  • 유형별
    • 관상 동맥 스텐트 유치
    • 말초 스텐트 유치
  • 스캐폴드별
    • 플래티넘 크롬
    • 코발트 크롬
    • 니티놀
    • 기타
  • 코팅별
    • 폴리머 베이스 코팅
    • 폴리머 프리 코팅
  • 약물 유형별
    • 에베롤리무스
    • 파클리탁셀
  • 최종 사용자별
    • 병원
    • 외래수술센터(ASC)
    • 전문 클리닉
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 기타 지역

제8장 약물 용출 스텐트 시장 : 기업?제품 프로파일

  • Medtronic
  • Abbott
  • Boston Scientific Corporation
  • B. Braun Melsungen AG
  • BIOTRONIK SE & Co. KG
  • Cook
  • Terumo Corporation
  • Lepu Medical Technology Co.,Ltd
  • Microport Scientific Corporation
  • Balton Sp.zoo
  • ENDOCOR GmbH
  • Eurocor Tech GmbH
  • Alvimedica
  • Biosensors International Group, Ltd.
  • Meril Life Sciences Pvt. Ltd.
  • Translumina
  • Sino Medical Sciences Technology Inc.
  • iVascular SLU
  • Sahajanand Laser Technology Limited
  • Cardionovum GmbH

제9장 KOL의 견해

제10장 프로젝트 접근법

제11장 DelveInsight 정보

제12장 면책사항 및 문의

JHS 25.01.09

Drug-Eluting Stents Market by Type (Coronary Stenting and Peripheral Stenting), Scaffold (Platinum-Chromium, Cobalt-Chromium, Nitinol, and Others), Coating (Polymer-based Coating [Biodegradable and Non-biodegradable] and Polymer-free Coating), Drug Type (Everomilus, Paclitaxel, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a substantial CAGR forecast till 2030 owing to the increasing cases of cardiovascular disorders and the rising product developmental activities worldwide

The drug-eluting stents market was valued at USD 2.40 billion in 2023, growing at a CAGR of 7.88% during the forecast period from 2024 to 2030 to reach USD 3.78 billion by 2030. The drug-eluting stents market is observing substantial market growth primarily owing to the increasing cases of cardiovascular disorders including atrial fibrillation and coronary artery disease (CAD), peripheral artery disease (PAD), innovative product developmental activities by regulatory bodies, and the rising adoption of minimally invasive techniques that are expected to escalate the overall growth of the drug-eluting stents market during the forecast period from 2024 to 2030.

Drug-Eluting Stents Market Dynamics:

As per data provided by the World Heart Report (2023), in 2021, it was stated that more than half a billion people were living with cardiovascular diseases globally. Further, according to recent data provided by the American Heart Association (2023), it is estimated that by 2030 over 12 million people will have atrial fibrillation globally.

According to British Heart Foundation, Global Heart & Circulatory Diseases Factsheet (2024), it stated that around 200 million people are living with coronary artery disease (CAD) around the world.

As per data by the American Heart Association (2023), around 200 million live with peripheral artery disease (PAD) globally on average. Also, as per the Global Burden of Disease (2019), there were 56.4 million prevalent cases of PAD among those aged 40 to 70, worldwide in 2019.

Thus, the rising instances of cardiovascular conditions are driving a significant increase in demand for drug-eluting stents. As these conditions become more widespread globally, the need for effective, minimally invasive treatments like stenting is growing. Advances in stent technology, along with the increasing burden of heart and circulatory diseases, are making stents a vital component in treating these conditions, enhancing their role in both preventive and therapeutic healthcare strategies.

Increased product developmental activities by regulatory bodies worldwide is also slated to drive the market growth for drug-eluting stents. For example, in May 2022, Medtronic announced that it received the U.S. Food and Drug Administration (FDA) approval for the Onyx Frontier(TM) drug-eluting stent (DES).

Hence, the interplay of all the above-mentioned factors is expected to drive the market for drug-eluting stents during the given forecast period from 2024 to 2030.

However, the risks and complications associated with drug-eluting stents, the stringent regulatory approval process, among others may prove to be challenging factors for the growth of the drug-eluting stents market.

Drug-Eluting Stents Market Segment Analysis:

Drug-Eluting Stents Market by Type (Coronary Stenting and Peripheral Stenting), Scaffold (Platinum-Chromium, Cobalt-Chromium, Nitinol, and Others), Coating (Polymer-based Coating [Biodegradable and Non-biodegradable] and Polymer-free Coating), Drug Type (Everomilus, Paclitaxel, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the coating segment of the drug-eluting stents market, the polymer-based coating category is expected to have a significant revenue share in 2023. This is due to the various features and applications of polymer-based coating of drug-eluting stents.

Polymer-based coatings on drug-eluting stents enhance the controlled release of therapeutic agents, making them highly effective in preventing restenosis in coronary arteries. These coatings are engineered to enable the gradual and targeted release of drugs, such as antiproliferative or anti-inflammatory agents, directly at the stent site. This helps in reducing smooth muscle cell proliferation and neointimal hyperplasia, which are common causes of restenosis. Additionally, polymers can be tailored for specific hydrophilicity and hydrophobicity, adjusting drug release rates to optimize therapeutic effects.

Applications of polymer-based coatings extend beyond coronary stents, as they are also used in peripheral artery disease, maintaining arterial patency in various vessels. Furthermore, these coatings can be combined with multiple drugs to address a broader range of complications, like restenosis and inflammation, providing versatile treatment options for different patient needs.

Therefore, the widespread uses of polymer-based coating, solidify the impact on the overall growth of the drug-eluting stents market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall drug-eluting stents market:

Among all the regions, North America is estimated to hold a significant revenue share in the drug-eluting stents market. This can be attributed to several factors including the high instances of CAD, myocardial infarction, and its associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure that are acting as key factors contributing to the growth of the drug-eluting stents market in the North America region during the forecast period from 2024 to 2030.

As per data provided by the National Institute of Health (2023), it stated that 20.5 million people in the US were living with CAD. Furthermore, according to data from the Centers for Disease Control and Prevention (2024), it was stated that 805,000 people in the US have a myocardial infarction (heart attack) every year on average. Furthermore, as per the same source, it was stated that heart disease is an umbrella term that encompasses numerous indications such as acute coronary syndrome, atherosclerosis, and congestive heart failure among others. Some of the key risk factors associated with heart disease are high blood cholesterol, high blood pressure, and smoking. The source further mentioned that about half of Americans (47%) have at least one of these three risk factors.

According to data from the Canadian Institute for Health Information (2024), it stated that in 2022, 2.4 million Canadians were affected by heart disease.

Since cardiovascular disorders are rising in the region among middle-aged individuals, the demand for more effective diagnostic and treatment options is increasing significantly. This trend is fueling investment in innovative technologies and expanding the market for drug-eluting stents.

Product developmental activities initiated by regulatory bodies will further boost the market for drug-eluting stents. For example, in March 2024, Boston Scientific Corporation announced that it received U.S. Food and Drug Administration (FDA) approval for the AGENT(TM) Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease.

The prompt and well-established healthcare services and infrastructure further contribute to the growth of the regional drug-eluting stents market growth. The presence of key players such as Abbott, Medtronic, and Boston Scientific Corporation with their strong distribution networks ensure widespread availability and accessibility of these devices across the region increasing their revenue shares in the market, and supportive reimbursement programs providing immense growth opportunities for the same.

Therefore, the interplay of all the factors mentioned above provides a conducive growth environment for the North America region in the drug-eluting stents market during the forecast period from 2024 to 2030.

Drug-Eluting Stents Market key players:

Some of the key market players operating in the drug-eluting stents market include Medtronic, Abbott, Boston Scientific Corporation, B. Braun Melsungen AG, BIOTRONIK SE & Co. KG, Cook, Terumo Corporation, Lepu Medical Technology Co., Ltd., Microport Scientific Corporation, Balton Sp.z.o.o, ENDOCOR GmbH, Eurocor Tech GmbH, Alvimedica, Biosensors International Group, Ltd., Meril Life Sciences Pvt. Ltd., Translumina, Sino Medical Sciences Technology Inc., iVascular S.L.U, Sahajanand Laser Technology Limited, Cardionovum GmbH, and others.

Recent Developmental Activities in the Drug-Eluting Stents Market:

  • In September 2021, Biotronik received regulatory approval from the US Food and Drug Administration for their Orsiro Mission bioabsorbable polymer drug-eluting stent system (BP-DES).
  • In June 2021, Abbott received product approval from the US FDA for their XIENCE family of stents for one-month (for 28 days) DAPT labeling for high bleeding risk (HBR) patients in the U.S.
  • In May 2021, Alvimedica received the CE mark approval for their NiTides self-expanding, drug-eluting stent, aimed for treating lesions associated with peripheral artery disease in the superficial femoral arteries.

Key takeaways from the Drug-Eluting Stents Market Report study

  • Market size analysis for current drug-eluting stents market size (2023), and market forecast for 6 years (2024 to 2030)
  • Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
  • Key companies dominating the drug-eluting stents market
  • Various opportunities available for other competitors in the drug-eluting stents market space
  • What are the top-performing segments in 2023? How these segments will perform in 2030?
  • Which are the top-performing regions and countries in the current drug-eluting stents market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for drug-eluting stents market growth in the coming future?

Target audience who can be benefited from this drug-eluting stents market report study

  • Drug-eluting stents providers
  • Research organizations and consulting companies
  • Drug-eluting stents related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in drug-eluting stents
  • Various end-users who want to know more about the drug-eluting stents market and the latest developments in the drug-eluting stents market

Frequently Asked Questions for the Drug-Eluting Stents Market:

1. What are drug-eluting stents?

  • The drug-eluting stent is a small mesh structure that is inserted into the artery to keep it open and also releases a medication that helps in preventing the formation of blood clots inside the stent.

2. What is the market for drug-eluting stents?

  • The drug-eluting stents market was valued at USD 2.40 billion in 2023, growing at a CAGR of 7.88% during the forecast period from 2024 to 2030 to reach USD 3.78 billion by 2030.

3. What are the drivers for the drug-eluting stents?

  • The drug-eluting stents market is observing substantial market growth primarily owing to the increasing cases of cardiovascular disorders including atrial fibrillation and coronary artery disease (CAD), peripheral artery disease (PAD), innovative product developmental activities by regulatory bodies, and the rising adoption of minimally invasive techniques that are expected to escalate the overall growth of the drug-eluting stents market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the drug-eluting stents?

  • Some of the major market players operating in the drug-eluting stents market include Medtronic, Abbott, Boston Scientific Corporation, B. Braun Melsungen AG, BIOTRONIK SE & Co. KG, Cook, Terumo Corporation, Lepu Medical Technology Co.,Ltd., Microport Scientific Corporation, Balton Sp.z.o.o, ENDOCOR GmbH, Eurocor Tech GmbH, Alvimedica, Biosensors International Group, Ltd., Meril Life Sciences Pvt. Ltd., Translumina, Sino Medical Sciences Technology Inc., iVascular S.L.U, Sahajanand Laser Technology Limited, Cardionovum GmbH, and others.

5. Which region has the highest share in the drug-eluting stents?

  • Among all the regions, North America is estimated to hold a significant revenue share in the drug-eluting stents market. This can be attributed to several factors including the high instances of CAD, myocardial infarction, and its associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure that are acting as key factors contributing to the growth of the drug-eluting stents market in the North America region during the forecast period from 2024 to 2030.

Table of Contents

1. Drug-Eluting Stents Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Drug-Eluting Stents Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Drug-Eluting Stents Market Key Factors Analysis

  • 5.1. Drug-Eluting Stents Market Drivers
    • 5.1.1. Increasing incidence of chronic disorders
    • 5.1.2. Rising product developmental activities
    • 5.1.3. Growing instances of life-style related disorders
    • 5.1.4. Increasing preference for minimally invasive procedures
  • 5.2. Drug-Eluting Stents Market Restraints and Challenges
    • 5.2.1. Risk and complications associated with drug-eluting stents
    • 5.2.2. Stringent regulatory approval process
  • 5.3. Drug-Eluting Stents Market Opportunities
    • 5.3.1. Development of bioresorbable vascular scaffolds
    • 5.3.2. Integrating AI and robotics for stent placement

6. Drug-Eluting Stents Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Drug-Eluting Stents Market Assessment

  • 7.1. By Type
    • 7.1.1. Coronary Stenting
    • 7.1.2. Peripheral Stenting
  • 7.2. By Scaffold
    • 7.2.1. Platinum-Chromium
    • 7.2.2. Cobalt-Chromium
    • 7.2.3. Nitinol
    • 7.2.4. Others
  • 7.3. By Coating
    • 7.3.1. Polymer-based Coating
      • 7.3.1.1. Biodegradable
      • 7.3.1.2. Non-Biodegradable
    • 7.3.2. Polymer-Free Coating
  • 7.4. By Drug Type
    • 7.4.1. Everolimus
    • 7.4.2. Paclitaxel
    • 7.4.3. Others
  • 7.5. By End-User
    • 7.5.1. Hospitals
    • 7.5.2. Ambulatory Surgical Centers
    • 7.5.3. Specialty Clinics
  • 7.6. By Geography
    • 7.6.1. North America
      • 7.6.1.1. United States Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.1.2. Canada Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.1.3. Mexico Drug-Eluting Stents Market Size in USD million (2021-2030)
    • 7.6.2. Europe
      • 7.6.2.1. France Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.2.2. Germany Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.2.3. United Kingdom Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.2.4. Italy Drug-Eluting Stents market size in USD million (2021-2030)
      • 7.6.2.5. Spain Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.2.6. Rest of Europe Drug-Eluting Stents Market Size in USD million (2021-2030)
    • 7.6.3. Asia-Pacific
      • 7.6.3.1. China Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.3.2. Japan Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.3.3. India Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.3.4. Australia Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.3.5. South Korea Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.3.6. Rest of Asia-Pacific Drug-Eluting Stents Market Size in USD million (2021-2030)
    • 7.6.4. Rest of the World (RoW)
      • 7.6.4.1. Middle East Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.4.2. Africa Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.4.3. South America Drug-Eluting Stents Market Size in USD million (2021-2030)

8. Drug-Eluting Stents Market Company and Product Profiles

  • 8.1. Medtronic
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Abbott
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Boston Scientific Corporation
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. B. Braun Melsungen AG
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. BIOTRONIK SE & Co. KG
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Cook
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Terumo Corporation
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Lepu Medical Technology Co.,Ltd
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Microport Scientific Corporation
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Balton Sp.z.o.o
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. ENDOCOR GmbH
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Eurocor Tech GmbH
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Alvimedica
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Biosensors International Group, Ltd.
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Meril Life Sciences Pvt. Ltd.
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Translumina
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Sino Medical Sciences Technology Inc.
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. iVascular S.L.U
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Sahajanand Laser Technology Limited
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Cardionovum GmbH
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제